A new study conducted by researchers at the Nizam's Institute of Medical Sciences in Hyderabad, India found that Withania somnifera (Sensoril from Natreon, Inc.) significantly improved cognitive and psychomotor performance in healthy subjects (Pharmacognosy Res. 2014 Jan-March;6(1):12-18).
In the double-blind, multi-dose, placebo-controlled crossover study, 20 healthy male participants received two, 250 mg capsules of Sensoril or a matching placebo twice a day for 14 days. Cognitive and pyschomotor performance were assessed on day one, before the doses were given and three hours post-dose on day 15. The participants were assessed using tests including finger tapping, simple reaction, choice discrimination, digit symbol substitution, digit vigilance and card sorting tests. These particular tests are widely used in clinical studies due to their sensitivity and validity for detecting changes in psychomotor performance in healthy subjects. After a washout period of 14 days, the participants then crossed-over to receive the other treatment, using the previous schedule and testing procedures.
Significant improvements in reaction times in all the assessment tests, excluding finger tapping, were observed in the participants taking Sensoril. These results suggest that Sensoril can improve cognitive and psychomotor performance and may be valuable in the treatment of diseases associated with cognitive impairment.
We are delighted with the results of this study and the compelling data which this research has revealed about Sensorils ability to enhance cognitive and psychomotor performance said Sanni Raju, Ph.D., CEO and chairman of the board of Natreon, Inc. Our commitment to building the research and intellectual property platform for Sensoril on behalf of our customers and partners has been and always will be our first priority."